Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals is an Australia-based, ASX-listed late-stage biopharmaceutical company focused on developing pentosan polysulfate sodium for inflammatory and degenerative diseases. Its lead asset is injectable pentosan polysulfate sodium, branded Zilosul®, which is being advanced in Phase 3 development for osteoarthritis. The company positions itself as a molecule-repurposing developer, seeking to unlock new clinical value from underutilised compounds with existing safety and manufacturing foundations. Beyond osteoarthritis, Paradigm has described additional development interest in mucopolysaccharidoses, alphavirus-induced arthralgia, heart failure, acute respiratory distress syndrome, and allergic rhinitis. The business operates with a lean outsourced development model and has headquarters in Melbourne with offices in the United States and Europe.